Latest News and Press Releases

CAMBRIDGE, Mass., Sept. 09, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (“CoLucid”) (Nasdaq:CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute...

CAMBRIDGE, Mass., Sept. 08, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (“CoLucid”) (Nasdaq:CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute...

100 mg and 200 mg doses of lasmiditan efficacious on headache pain freedom and most bothersome symptom free at the two-hour time point (p < 0.001)Lasmiditan was well tolerated with no significant...

CAMBRIDGE, Mass., Aug. 10, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) today reported financial and operating results for the quarter ended June 30, 2016.  Corporate...

CAMBRIDGE, Mass., June 22, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc., (Nasdaq:CLCD) a Phase 3 clinical-stage biopharmaceutical company that is developing lasmiditan oral tablets for the...

CAMBRIDGE, Mass., June 07, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing lasmiditan oral tablets for the...

CAMBRIDGE, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing lasmiditan oral tablets for the...

First Patient Randomized in SPARTAN StudyTrial Being Conducted Under Special Protocol Assessment Agreement with FDA CAMBRIDGE, Mass., May 19, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals,...

CAMBRIDGE, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) today reported financial and operating results for the first quarter ended March 31, 2016. Corporate...

CAMBRIDGE, Mass., March 15, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate,...